Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.58 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.58 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | FAP | Q12884 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14982932 | 0.95 | DPP4 (0.53) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL2162213 | 0.89 | DPP4 (0.60) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL10057496 | 0.89 | DPP4 (0.60) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL14985846 | 0.88 | DPP4 (0.55) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL573033 | 0.88 | DPP4 (0.55) | DPP4DPP8DPP7DPP9ACE | |
| Sitagliptin Fenilalanil SCHEMBL10057466 | 0.87 | DPP4 (0.68) | DPP4DPP8DPP7DPP9ACE | |
| Sitagliptin Fenilalanil SCHEMBL2555445 | 0.87 | DPP4 (0.68) | DPP4DPP8DPP7DPP9ACE | |
| Sitagliptin Fenilalanil SCHEMBL572080 | 0.86 | DPP4 (0.68) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL15471558 | 0.85 | DPP4 (0.57) | DPP4DPP8DPP7DPP9ACE | |
| SCHEMBL15471565 | 0.85 | DPP4 (0.57) | DPP4DPP8DPP7DPP9ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | Cadila Corporate Campus (IN) | 2013-05-30 | — | — | US | disclosed |
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | Cadila Corporate Campus (IN) | 2013-05-30 | — | — | US | disclosed |
| WO-2012017391-A2 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | CADILA PHARMACEUTICALS LIMITED (IN) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 5/4885DPP7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.